On April 12, 2023 Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, reported that it will present new data highlighting the company’s novel technology and approaches to early cancer detection at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, April 14-19, in Orlando, Florida (Press release, Exact Sciences, APR 12, 2023, View Source [SID1234629991]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Exact Sciences’ data presentations support its blood-based, multi-cancer early detection (MCED) test, initial data for the company’s molecular residual disease (MRD) technologies, strategies to improve colorectal cancer screening outcomes, and a study involving the OncoExTra test, which uses next-generation sequencing (NGS) to assess a tumor’s RNA and DNA to help inform treatment decisions.
"Our data at AACR (Free AACR Whitepaper) show notable progress across our pipeline of cancer tests, from screening to late-stage therapy selection," said Jorge Garces, Ph.D., chief science officer, Exact Sciences. "The potential of MCED tests to detect many cancers from one blood draw is an incredible advancement for healthcare providers and their patients, and our data inform the optimal approach to identify where the cancer is located."
Data presentations across Exact Sciences’ Screening and Precision Oncology portfolios at AACR (Free AACR Whitepaper) 2023:
Poster #769: Evaluating the diagnostic burden of tumor localization strategies for multi-cancer early detection tests
Data embargoed until 1:30 p.m. ET on Sunday, April 16
Authors: Tyson, C, et al.
Date/Time: Sunday, April 16, 1:30 p.m. – 5:00 p.m. ET
Location: Section 28
Summary: In this analysis, advanced imaging identified the tissue of cancer origin following a positive MCED test resulting in fewer procedures to achieve cancer diagnosis when compared to molecular testing.
Poster #6694: Evaluation of a multi-omics approach to molecular residual disease detection
Data embargoed until 9:00 a.m. ET on Wednesday, April 19
Authors: Culver B, et al.
Date/Time: Wednesday, April 19, 9:00 a.m. – 12:30 p.m. ET
Location: Section 40
Summary: MRD methodologies developed using variants specifically derived from the patient tumor (tumor-informed) and a pre-defined set of markers (tumor-agnostic) showed high concordance in cancer detection and complemented each other in differentiating cancer samples from non-cancer samples.
Poster #770: Provider communication contributes to colorectal cancer screening intention through improving screening outcome expectancies and perceived behavioral control
Data embargoed until 1:30 p.m. ET on Sunday, April 16
Authors: Zhu X, et al.
Date/Time: Sunday, April 16, 1:30 p.m. – 5:00 p.m. ET
Location: Section 28
Summary: Improving health care provider communication with patients regarding beliefs about the effectiveness and ease of use of multi-target stool DNA screening may contribute to colorectal screening completion.
Poster #2150: CLDN18/ARHGAP26 in gastric cancers
Data embargoed until 9:00 a.m. ET on Monday, April 17
Authors: Josefson D, et al.
Date/Time: Monday, April 17, 9:00 a.m. – 12:30 p.m. ET
Location: Section 39
Summary: OncoExTra, an ultra-comprehensive DNA and RNA-based genomic test, was used to examine the prevalence of gastric cancer fusion CLDN18/ARHGAP26, that has been known to appear more often in young females and is associated with a poor prognosis and higher likelihood of metastasis.